Today, one micro-cap biotech delivered an encouraging patent update, sparking renewed enthusiasm among shareholders and sending its stock higher on the news. Shares of BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF), a bioscience company focused on advanced drug delivery technologies, are ticking higher on the company’s announcement that the Eurasian Patent Organization (EAPO) has issued a “Readiness to Grant” notice for its patent covering sublingual delivery of anticancer drugs for autoimmune neurodegenerative diseases. The patent supports multiple proprietary product and commercialization pathways, including BioNxt’s flagship candidate, BNT23001 — a sublingual thin-film formulation of Cladribine designed for treating multiple sclerosis (MS).
The EAPO is expected to formally grant the patent once BioNxt completes the publication fee payment this week. The Eurasian Patent Convention spans eight countries — Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, and Turkmenistan — offering protection across a market of more than 200 million people. Meanwhile, BioNxt continues its patent nationalization efforts in other key jurisdictions, including the EU, Canada, Australia, New Zealand, Japan, and the U.S. under a Track One expedited process. Patent authorities in both Europe and Eurasia have confirmed the invention’s novelty, inventive step, and industrial applicability.
"Solidifying patent protection is a critical part of our commercialization strategy," said Hugh Rogers, CEO of BioNxt. "The timing is excellent as the Company is days away from commencing a two-week-long large-mass animal bioequivalence study to determine dosing parameters for our upcoming human bioequivalence study. The coming months are expected to be very exciting for BioNxt as multiple clinical programs advance and our intellectual property portfolio gains international recognition and protection."
Shares of BNXT are currently trading up 2.41% at $0.85, while U.S. listed shares (BNXTF) move higher by 2.53% at $0.6152 in late-morning trading.
Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
View more of this article on AllPennyStocks.com.
About AllPennyStocks.com Media, Inc.:
Founded in 1999, AllPennyStocks.com is one of North America’s leading platforms for micro-cap insights.
Catering to both Canadian and U.S. markets, we provide a wealth of resources and expert content designed for everyone—from beginner investors to seasoned traders.
AllPennyStocks.com is rapidly gaining recognition as a leading authority in the micro-cap space, with our insightful content prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.
Want to showcase your company's story to a powerful network of investors? We can help you elevate your message and make a lasting impact. Contact us today.
Contact:
AllPennyStocks.com Media, Inc.
Email: ads@allpennystocks.com
Phone: (800) 558-4560 Ext: 101
]]>
